Rimegepant: Effective Relief for Menstrual Migraines in Women
- Apr 4
- 1 min read
Research Summary
A new study published in BMC Neurology explores the efficacy and safety of rimegepant for treating pure menstrual migraine in Chinese women. This retrospective observational study highlights that rimegepant, at a dose of 75 mg, significantly reduces migraine symptoms in this specific population. The researchers observed a notable decrease in headache intensity and duration, alongside an improvement in overall quality of life. Importantly, the treatment was well-tolerated, with only mild side effects reported, emphasizing its potential as a viable option for managing menstrual migraines. This study provides crucial insights into targeted migraine therapies for women, offering hope for more personalized treatment approaches.
Study Details
👥 Research Team: Ye W et al.
📚 Published In: BMC Neurol
📅 Publication Date: 2026 Apr 2
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.